FDA RGEN-101 coverage for business development, investment, and market access teams
The FDA has granted approval for RGEN-101, an innovative orphan drug by RareGen, targeting a rare genetic disorder and promising new treatment options.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
